Lido Advisors
IMNM icon

Lido Advisors’s Immunome IMNM Stock Holding History

Lido Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
49,341
+391
+0.8% +$8.37K ﹤0.01% 1071
2026
Q1 		$1.07M Sell
48,950
-10,101
-17% -$225K ﹤0.01% 942
2025
Q4 		$691K Hold
59,051
– – ﹤0.01% 1153
2025
Q3 		$691K Sell
59,051
-34
-0.1% -$338 ﹤0.01% 1095
2025
Q2 		$549K Buy
59,085
+6,085
+11% +$49.9K ﹤0.01% 1080
2025
Q1 		$357K Buy
+53,000
New +$508K ﹤0.01% 1142

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Lido Advisors's IMNM Position: Q2 2026 in Review

Lido Advisors increased its Immunome (IMNM) stake by 0.8% in Q2 2026, buying an estimated $8.37K and bringing the position to 49,341 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Lido Advisors first reported a position in IMNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.07M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Lido Advisors held 49,341 shares of Immunome worth $1.05M as of Q2 2026.
  • Lido Advisors bought 391 Immunome shares in Q2 2026, an estimated $8.37K.
  • Immunome made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1071 holding.
  • Lido Advisors first reported a position in Immunome in Q1 2025 and has held it in 6 quarters since.
  • Lido Advisors's Immunome position peaked at $1.07M in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.